Undergraduate: University of Konstanz, Germany
Post-doctoral: University of Colorado School of Medicineįun Fact: Once stared a polar bear in the eye from one foot away.Ĭurrent Project: Elucidating the molecular pathways that synergize with MERTK inhibition in acute myeloid leukemia.įun Fact: I enjoy pyrography because it allows me to customize gifts for friends and family. Graduate Studies: University of California- Berkeley Post-doctoral: University of Colorado/Children's Hospital Coloradoįun Fact: I once rappelled down the tallest building in Denver to raise money for cancer research. Graduate Studies: University of North Carolina (MD, PhD) We are also working with collaborators to develop additional classes of novel inhibitors targeting the TAM kinases.
The lead compound, MRX-2843, is a first-in-class dual MERTK and FLT3-selective tyrosine kinase inhibitor that is currently being tested in phase I clinical trials. Studies to determine the optimal application of MERTK inhibitors in combination with other agents to maximize therapeutic effects are ongoing. In addition, we developed and characterized a series of novel small molecules that selectively and potently inhibit MERTK with the goal of targeting MERTK to treat patients with cancer. Current projects focused on acute leukemia, non-small cell lung cancer and melanoma are aimed at better understanding the biology of MERTK and related receptors in tumor cells and their roles in the human immune system. Graham and subsequent work in the Graham lab demonstrated oncogenic roles for MERTK in a variety of solid tumor and hematologic malignancies. The receptor tyrosine kinase MERTK was first discovered by Dr. Welcome! We study members of the TAM-family of receptor tyrosine kinases (TYRO3, AXL, and MERTK) in cancer and the effects of TAM inhibition asa disease treatment.
0 kommentar(er)
